Regeneron Pharma (NASDAQ:REGN) reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Regeneron Pharma announced earnings per share of $7.5 on revenue of $2.17B. Analysts polled by anticipated EPS of $7.18 on revenue of $2.11B. That with comparison to EPS of $6.84 on revenue of $1.93B in the same period a year before. Regeneron Pharma had reported EPS of $6.67 on revenue of $2.05B in the previous quarter. Analysts are expecting EPS of $6.46 and revenue of $2.05B in the upcoming quarter.
Regeneron Pharma shares are down 0.88% from the beginning of the year , still down 15.80% from its 52 week high of $442.00 set on March 4, 2019. They are under-performing the Nasdaq which is up 5.19% year to date.
Regeneron Pharma follows other major Healthcare sector earnings this month
Regeneron Pharma's report follows an earnings beat by J&J on January 22, who reported EPS of $1.88 on revenue of $20.75B, compared to forecasts EPS of $1.87 on revenue of $20.8B.
Merck&Co had beat expectations on Wednesday with fourth quarter EPS of $1.16 on revenue of $11.87B, compared to forecast for EPS of $1.15 on revenue of $11.95B.
Stay up-to-date on all of the upcoming earnings reports by visiting 's earnings calendar
